Protagenic Therapeutics Warrant
PTIXW
PTIXW was delisted on the 2nd of January, 2026.
2 hedge funds and large institutions have $6.32K invested in Protagenic Therapeutics Warrant in 2023 Q2 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, 1 reducing their positions, and 1 closing their positions.
20% more capital invested
Capital invested by funds: $5.26K → $6.32K (+$1.05K)
3.09% more ownership
Funds ownership: 1.26% → 4.35% (+3.1%)
33% less funds holding
Funds holding: 3 → 2 (-1)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JMPWA
JP Morgan Private Wealth Advisors
San Francisco,
California
|
-$600 |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$131 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
WAM
1
Warberg Asset Management
Winnetka,
Illinois
| $5.94K | – | – | – |
|
|
2
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $379 | -$131 | -4,184 | -27% |
|
|
JMPWA
3
JP Morgan Private Wealth Advisors
San Francisco,
California
| – | -$600 | -25,000 | Closed |
|
PTIXW Hedge Fund Activity: Q2 2023 in Review
2 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Protagenic Therapeutics Warrant (PTIXW) for Q2 2023, worth a combined $6.32K — up 20% from $5.26K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of PTIXW and 0 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 0 added.
The largest seller was JP Morgan Private Wealth Advisors, exiting entirely with an estimated $600 sold.
- 2 institutional investors held Protagenic Therapeutics Warrant (PTIXW) as of Q2 2023, down from 3 in Q1 2023.
- Funds reported $6.32K of Protagenic Therapeutics Warrant stock for Q2 2023, up 20% quarter-over-quarter.
- 0 funds opened new Protagenic Therapeutics Warrant positions in Q2 2023 and 1 closed out, a net change of -1 holder.
- The largest Protagenic Therapeutics Warrant seller in Q2 2023 was JP Morgan Private Wealth Advisors, an estimated $600 sold.
Based on aggregated 13F filings for Q2 2023.